Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 1Hypothyroidism 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 284Drug Therapy 244apatinib 242Bevacizumab 230camrelizumab 214Etoposide 200Irinotecan 177Doxorubicin 175Leucovorin 162Dexamethasone 160sintilimab 142pembrolizumab 140anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × Thyroid (USP) × Clear all
NCT05247476 2022-02-18

Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.

Zhongshan Hospital Xiamen University

Phase 4 Unknown
50 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Hypothyroidism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡